GenScript Biotech Awarded EcoVadis Silver Medal Once Again, Ranking in the Top 8% Globally for Sustainability

February 9, 2026

Piscataway, NJ, February 9, 2026– GenScript Biotech Corporation (HK.1548), a global leader in life science R&D and manufacturing services, today announced that the company has once again been awarded the Silver Medal rating by EcoVadis, the internationally recognized corporate sustainability assessment authority. This marks the second consecutive year that GenScript has received this distinction, demonstrating continuous progress across four key dimensions: environment, labor and human rights, business ethics, and sustainable procurement.

EcoVadis Silver Medal for the Second Consecutive Year

According to EcoVadis’ latest results, GenScript’s sustainability performance now ranks within the top 8% of all assessed companies worldwide, and top 5% within the basic pharmaceutical products and pharmaceutical preparations manufacturing sector. As a leading global assessment platform covering more than 180 countries and 220 industries, EcoVadis adheres to internationally recognized standards, including the UN Global Compact (UNGC), Global Reporting Initiative (GRI), and ISO 26000, and is widely regarded as the “gold standard” for corporate sustainability evaluations.

Winning the Silver Medal for two consecutive years not only reflects GenScript’s steady enhancements to its ESG management systems but also reinforces the company’s strong commitment to being a trusted global partner to customers worldwide.

GenScript Group Rotating CEO Sherry Shao stated:
“Being awarded the EcoVadis Silver Medal for two consecutive years marks another solid step forward in our sustainability journey. This recognition underscores our long term commitment to environmental management, social responsibility, and business ethics, and demonstrates our dedication to building a sustainable global supply chain. Over the years, GenScript has integrated sustainability principles throughout our full operational lifecycle, advancing both internal operations and helping customers achieve their sustainability goals through technological innovation and global collaboration.”

Multiple International Recognitions Demonstrate GenScript’s ESG Strength

GenScript’s sustainability efforts have earned multiple prestigious global recognitions. As a member of the UN Global Compact (UNGC), the company actively upholds the ten principles on human rights, labor, environment, and anti corruption. As a Pharmaceutical Supply Chain Initiative (PSCI) supplier partner, GenScript also contributes to developing sustainable supply chains across the pharmaceutical industry.

The company has received an MSCI ESG AA rating, a Sustainalytics Low Risk rating, and has been included in the FTSE4Good Index Series, showcasing its strong overall ESG performance. In addition, GenScript’s decarbonization targets have been validated by the Science Based Targets initiative (SBTi), further demonstrating the company’s concrete commitment to addressing climate change.

Looking Ahead

GenScript will continue to uphold its mission — “Make People and Nature Healthier Through Biotechnology” — and further integrate sustainability principles into its global strategy. Through continuous innovation and industry collaboration, the company aims to drive the biopharmaceutical sector toward a greener and more responsible future, contributing meaningful value to human health and global sustainable development.

About GenScript Biotech

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop ground breaking treatments and products. As a cornerstone of the global life science ecosystem, GenScript actively collaborates with a diverse network of partners—from academic institutions to industry leaders—to co-create cutting-edge solutions that redefine service excellence. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript has become a trusted global partner with a team of 5,500+ employees, supporting over 200,000 customers across 100+ countries and regions, including the world’s Top 20 pharma companies.